Provided by Tiger Fintech (Singapore) Pte. Ltd.

SYNAPTOGENIX, INC.

3.58
-0.7200-16.74%
Post-market: 3.970.3900+10.89%19:50 EDT
Volume:264.61K
Turnover:963.04K
Market Cap:4.98M
PE:-0.36
High:4.28
Open:4.25
Low:3.25
Close:4.30
Loading ...

Company Profile

Company Name:
SYNAPTOGENIX, INC.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
4
Office Location:
1185 Avenue of the Americas,3rd Floor,New York,New York,United States
Zip Code:
10036
Fax:
- -
Introduction:
Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.

Directors

Name
Position
Alan J. Tuchmam
Director,Chief Executive Officer
Joshua Silverman
Chairman of the Board,Director
William S. Singer
Director, Vice-Chairman of the Board
Daniel L. Alkon
Director,President and Chief Scientific Officer
Bruce T. Bernstein
Director
Jonathan L. Schechter
Director

Shareholders

Name
Position
Alan J. Tuchmam
Director,Chief Executive Officer
Robert Weinstein
Chief Financial Officer, Secretary and Executive Vice President
Daniel L. Alkon
Director,President and Chief Scientific Officer